Director Makes Bold Move with Million-Dollar Vivani Medical Stock Purchase

New insider activity at Vivani Medical ( (VANI) ) has taken place on October 16, 2025.

Director Gregg Williams has made a significant investment in Vivani Medical by purchasing 1,737,764 shares of the company’s stock. This transaction is valued at an impressive $1,983,332, showcasing his confidence in the company’s future prospects.

Recent Updates on VANI stock

Vivani Medical recently announced the temporary withdrawal of the record date for the spin-off of its subsidiary, Cortigent, Inc., due to delays caused by the U.S. federal government shutdown. Cortigent, which focuses on brain implant devices with neuromodulation technology, is expected to have a new record date announced shortly. Analysts have maintained a Buy rating on Vivani Medical stock, with a price target reflecting confidence in the company’s strategic focus on its core drug implant business and recent milestones. However, challenges such as consistent losses and reliance on external financing continue to impact its financial outlook. The spin-off aims to enhance operational flexibility and provide direct investment opportunities in Cortigent’s pioneering technologies.

Spark’s Take on VANI Stock

According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.

Vivani Medical’s overall score reflects its challenging financial situation and unfavorable valuation. Despite some positive corporate events and neutral technical indicators, the company’s consistent losses and reliance on external financing weigh heavily on the score. The strategic focus on core drug implant business and recent milestones offer some potential for improvement, but substantial operational and financial efficiency improvements are necessary for a stronger outlook.

To see Spark’s full report on VANI stock, click here.

More about Vivani Medical

YTD Price Performance: 10.0%

Average Trading Volume: 141,036

Technical Sentiment Signal: Sell

Current Market Cap: $78.2M